Appili Therapeutics IncOTC Pink - Current Information:APLIFView on Canadian Exchange
- LAST PRICE0.0254
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots0.0215/ 500
- Ask / Lots0.0325/ 950
- Open / Previous Close--- / 0.0254
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
Nov 8, 2024
Aditxt Provides Update on Equity Line of Credit, ATM Usage, and Outstanding Number of Shares, from 8:30AM ET on Friday Nov 08, 2024 by Dow Jones
8:30AM ET on Friday Nov 08, 2024 by Dow Jones
Nov 7, 2024
Aditxt's Target Acquisition Appili Therapeutics Announces Results of Special Meeting of Shareholders, from 8:30AM ET on Thursday Nov 07, 2024 by Dow Jones
8:30AM ET on Thursday Nov 07, 2024 by Dow JonesPress Release: Aditxt's Target Acquisition Appili Therapeutics Announces Results of Special Meeting of Shareholders, from 8:30AM ET on Thursday Nov 07, 2024 by Dow Jones
8:30AM ET on Thursday Nov 07, 2024 by Dow Jones
Nov 6, 2024
Appili Therapeutics Announces Results of Special Meeting of Shareholders, from 5:55PM ET on Wednesday Nov 06, 2024 by Dow Jones
5:55PM ET on Wednesday Nov 06, 2024 by Dow JonesAditxt Acquisition Target Evofem Biosciences Secures Investor Support Through Voting Agreements for Merger with Aditxt's Subsidiary Adifem, from 8:30AM ET on Wednesday Nov 06, 2024 by Dow Jones
8:30AM ET on Wednesday Nov 06, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Appili Therapeutics Inc | 4.2M | --- | --- |
Company Information
Appili Therapeutics Inc. is a Canada-based biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures. The Company is advancing a diverse range of anti-infectives, including ready-made suspension of metronidazole for the treatment of antimicrobial infections, a vaccine candidate to eliminate a serious biological weapon threat, and a topical antiparasitic for the treatment of a disfiguring disease. Its anti-infective product development portfolio includes three programs: LIKMEZ (ATI-1501), ATI-1701 and ATI-1801. LIKMEZ (ATI-1501) is its advanced commercial stage asset, a liquid oral reformulation of the antibiotic metronidazole to treat serious anaerobic and protozoal infections. ATI-1701 is a live-attenuated vaccine for Francisella tularensis (F. tularensis), the bacterium which causes tularemia. ATI-1801 is a topical formulation of paromomycin (15% w/w) under advanced clinical development for the treatment of cutaneous leishmaniasis.
Contact Information
- Headquarters
- #21-1344 Summer StreetHALIFAX, NS, Canada B3H 0A8
- Phone
- 902-442-4655
- Fax
- 902-442-4655
Executives
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $4.2M |
|---|---|
Revenue (TTM) | $827.4K |
Shares Outstanding | 121.3M |
Appili Therapeutics Inc does not pay a dividend. | |
Beta | 0.95 |
EPS | $-0.03 |
Book Value | $-0.09 |
P/E Ratio | --- |
Price/Sales (TTM) | 5.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,039.87% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
